Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
Completed · Phase 1
Conditions studied: Inflammatory Disease
In brief
The primary objective of this study is to evaluate the pharmacokinetics (PK) of lanraplenib in participants with impaired renal function relative to matched healthy controls. Participants in this study will be enrolled using an adaptive design that includes up to 3 enrolled cohorts. Based on safety and/or PK data in Cohort 1, participants will be enrolled in adaptive Cohorts 2 and/or 3.
Key facts
- Study ID
- NCT02959138
- Run by
- Gilead Sciences
- People needed
- 36
- Starts
- 2016-11-21
- Expected to finish
- 2018-10-05
- Last updated by the study team
- 2019-10-25
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami, Inc. (CPMI) — Miami, Florida, United States
- Omega Research Consultants, LLC — Orlando, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- APEX GmBH — Munich, Germany
- Auckland Clinical Studies — Grafton, Auckland, New Zealand
- Christchurch Clinical Studies Trust — Christchurch, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.